Beam Therapeutics (BEAM) had its price target raised by Royal Bank Of Canada from $22.00 to $26.00. They now have a "sector perform" rating on the stock.
Beam Therapeutics (BEAM) had its price target raised by Wedbush from $57.00 to $65.00. They now have an "outperform" rating on the stock.
Beam Therapeutics Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Beam Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)